Skip to search boxSkip to navigationSkip to main content

Suppression of myeloid PFKFB3-driven glycolysis protects mice from choroidal neovascularization

  • Zhiping Liu
    ,
  • Xiaoxiao Mao
    ,
  • Qiuhua Yang
    ,
  • Xiaoyu Zhang
    ,
  • Jiean Xu
    ,
  • Qian Ma
Scholary Output:
Contribution to journal
Article
Peer-review

Abstract

BACKGROUND AND PURPOSE: Pathological angiogenesis is a major cause of irreversible blindness in individuals with neovascular age-related macular degeneration (nAMD). Macrophages and microglia (MΦ) contribute to aberrant ocular angiogenesis. However, the role of glucose metabolism of MΦ in nAMD is still undefined. Here, we have investigated the involvement of glycolysis, driven by the kinase/phosphatase PFKFB3, in the development of choroidal neovascularization (CNV).

EXPERIMENTAL APPROACH: CNV was induced in mice with laser photocoagulation. Choroid/retinal pigment epithelium (RPE) complexes and MΦ were isolated for analysis by qRT-PCR, western blot, flow cytometry, immunostaining, metabolic measurements and angiogenesis assays.

KEY RESULTS: MΦ accumulated within the CNV of murine nAMD models and expressed high levels of glycolysis-related enzymes and M1/M2 polarization markers. This phenotype of hyper-glycolytic and activated MΦ was replicated in bone marrow-derived macrophages stimulated by necrotic RPE in vitro. Myeloid cell-specific knockout of PFKFB3, a key glycolytic activator, attenuated pathological neovascularization in laser-induced CNV, which was associated with decreased expression of MΦ polarization markers and pro-angiogenic factors, along with decreased sprouting of vessels in choroid/RPE complexes. Mechanistically, necrotic RPE increased PFKFB3-driven glycolysis in macrophages, leading to activation of HIF-1α/HIF-2α and NF-κB, and subsequent induction of M1/M2 markers and pro-angiogenic cytokines, finally promoting macrophage reprogramming towards an angiogenic phenotype to facilitate development of CNV. The PFKFB3 inhibitor AZ67 also inhibited activation of HIF-1α/HIF-2α and NF-κB signalling and almost completely prevented laser-induced CNV in mice.

CONCLUSIONS AND IMPLICATIONS: Modulation of PFKFB3-mediated macrophage glycolysis and activation is a promising strategy for the treatment of nAMD.

Publication Information

Output type

Scholary Output:
Contribution to journal
Article
Peer-review

Original language

English (US)

Pages from-to (Number of pages)

Pages 5109-5131 (23 pages)

Journal (Volume, Issue Number)

British Journal of Pharmacology (Volume 179, Issue 22)

Publication milestones

  • Published - 11/2022

Publication status

Published - 11/2022

ISSN

0007-1188

Publication IDs

  • PubMed: 35830274
  • Scopus: 85135608016
  • PubMed: 35830274
  • ORCID: /0000-0002-0305-4122/work/124760269

Publication metrics

Metrics

Fractional count
3
Fractional count
0.20
Fractional count
12
Fractional count
0.80
Fractional count
3
Fractional count
1
Scopus
citations

PlumX, opens in new tab

Citation count
50
Captures
16

Funding Details

This Declaration acknowledges that this paper adheres to the principles for transparent reporting and scientific rigour of preclinical research as stated in the BJP guidelines for Design & Analysis, Immunoblotting and Immunochemistry, and Animal Experimentation, and as recommended by funding agencies, publishers and other organizations engaged with supporting research. This work is supported by National Natural Science Foundation of China Grant 81870324 to ZL; Shenzhen Science and Technology Innovation Committee Grants JCYJ20190808155801648 to MH; Shenzhen Fundamental Research Program GXWD20201231165807007-20200818123312001 to MH; Shenzhen-Hong Kong Institute of Brain Science–Shenzhen Fundamental Research Institutions 2019SHIBS0004 to MH; National Institutes of Health Grants R01EY030500 to RC and YH, R01EY033369 to RC and YH and R01 EY033733 to YH and RC; National Eye Institute of Center Core Grant P30EY031631 for Vision Research to Augusta University. This work is supported by National Natural Science Foundation of China Grant 81870324 to ZL; Shenzhen Science and Technology Innovation Committee Grants JCYJ20190808155801648 to MH; Shenzhen Fundamental Research Program GXWD20201231165807007‐20200818123312001 to MH; Shenzhen‐Hong Kong Institute of Brain Science–Shenzhen Fundamental Research Institutions 2019SHIBS0004 to MH; National Institutes of Health Grants R01EY030500 to RC and YH, R01EY033369 to RC and YH and R01 EY033733 to YH and RC; National Eye Institute of Center Core Grant P30EY031631 for Vision Research to Augusta University.